SBIPharma1

Developing and commercializing 5-aminolevulinic acid (5-ALA), an amino acid with multiple action mechanisms

SBI Pharmaceuticals is a Healthcare and Pharmaceutical company specializing in 5-ALA(Aminolevulinic acid). ALAGLIO® Divided Granules 1.5 g is a photodynamic diagnostic agent for bladder cancer currently on the market. It displays fluorescence in tumor cells as a unique characteristic under a specific wavelength of light. They also develop and sell medical devices to support the use of this drug. In addition, health foods containing ALA are developed to expand the potential of ALA. They contribute not only to human health, but also to other living organisms on the planet.

Invested in

2015

Base

Japan

Stage

Exit

Aquired by

Photonamic GmbH & Co. KG